Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Head and neck cancer patients receiving induction chemotherapy followed by radiation to preserve their larynx have a low-risk of severe voice disability and almost half experienced no eating or swallowing problems, according to a first of its kind study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

A comprehensive drug development strategy that starts with extensive screening of potential targeting agents and then narrows down to a small-molecule prototype has yielded two potential drugs that block cancer-promoting pathways in novel ways, a team led by scientists at The University of Texas M. D. Anderson Cancer Center reports in two papers published back-to-back online at the Proceedings of the National Academies of Science.

26 Feb 2010

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Multidisciplinary Head and Neck Cancer Symposium in Phoenix

The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting February 25-27, 2010, in Phoenix.

23 Feb 2010

Study shows CEL-2000 vaccine blocks RA progression in mice

CEL-SCI Corporation and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.

23 Feb 2010

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

The National Basketball Association's (NBA) Denver Nuggets Coach George Karl announced today that he has been diagnosed with treatable neck and throat cancer. According to published media reports, Karl's physician says the coach has cancer of his right tonsil that has spread to a lymph node in his neck. The 58-year-old Karl, who is also a prostate cancer survivor, coached in the NBA's All-Star game this past weekend.

22 Feb 2010

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Today GenVec, Inc. announced a new contract with the Department of Homeland Security to continue the development of adenovector-based vaccines against foot-and-mouth disease (FMD) based on research and development done in collaboration with USDA-ARS and DHS S&T scientists at the Plum Island Animal Disease Center.

19 Feb 2010

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

Patients with head and neck cancer linked to high risk human papillomavirus, or HPV, have worse outcomes if they are current or former tobacco users, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

15 Feb 2010

LUHS nurses earn professional certifications

Several Loyola University Health System (LUHS) nurses have earned professional certifications in their clinical areas of expertise. This indicates that LUHS nurses meet strong professional development standards and competencies.

11 Feb 2010

Renowned experts explore latest key development in nuclear medicine and molecular imaging at 2010 SNM summit

Educators, researchers, physicians, technologists and medical experts from across the country converged on Albuquerque, N.M., last week to explore topics in nuclear medicine, molecular imaging, nanomedicine and clinical trials during SNM's 2010 Conjoint Mid-Winter Meetings.

10 Feb 2010

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is pleased to announce that Cancer Research UK (CRUK), the UK philanthropy dedicated to cancer research, has agreed to fund the cost of a clinical trial to investigate the use of ADXS11-001, Advaxis’ lead human papilloma virus (HPV)-directed vaccine candidate, for the treatment of head and neck cancer.

10 Feb 2010

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

GenVec, Inc. announced today that data from the Company's trial in esophageal cancer were presented at the American Society of Clinical Oncology's 2010 Gastrointestinal Cancer Symposium in Orlando, Florida on January 22, 2010.

22 Jan 2010

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial by Merck KGaA of EMD 1201081, a novel agonist of Toll-like Receptor 9 (TLR9), in combination with cetuximab (Erbitux®) in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

20 Jan 2010

GenVec and Novartis collaborate to develop novel treatments for hearing loss and balance disorders

GenVec and Novartis will collaborate to discover and develop novel treatments for hearing loss and balance disorders. Preclinical results suggest that delivery of the atonal gene using GenVec's innovative adenovector technology may have the potential to restore hearing and balance function.

19 Jan 2010

PCI Biotech AS completes second dose group in phase I/II study of Amphinex

PCI Biotech AS ( PCIB.OL) reported today that it has completed the successful treatment of the second dose group in the phase I/II study of its proprietary photosensitiser Amphinex® used in combination with the cytotoxic agent bleomycin in cancer patients.

19 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

BioVex's Phase 3 melanoma study amended to include first line patients

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.

7 Jan 2010

FDA approves minimally invasive procedure for treating benign and malignant tumors

A minimally invasive surgical approach developed by head and neck surgeons at the University of Pennsylvania School of Medicine has been cleared by the U.S. Food and Drug Administration (FDA). The

5 Jan 2010

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Head and Neck Cancer News and Research

Larynx preservation using chemotherapy followed by radiation is effective treatment: Study

Comprehensive development strategy yields two potential drugs that block cancer-promoting pathways

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Multidisciplinary Head and Neck Cancer Symposium in Phoenix

Study shows CEL-2000 vaccine blocks RA progression in mice

Smokers, tobacco users and high alcohol consumers: Get mouths, gums and tongues checked for cancer

GenVec announces new contract with DHS to develop adenovector-based vaccines against FMD

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

LUHS nurses earn professional certifications

Renowned experts explore latest key development in nuclear medicine and molecular imaging at 2010 SNM summit

Advaxi to receive fund from CRUK for clinical trial of ADXS11-001

Data from GenVec's trial in esophageal cancer showcased at 2010 Gastrointestinal Cancer Symposium

Merck’s initiation of EMD 1201081-cetuximab combination Phase 2 trial triggers €3.0M milestone payment

GenVec and Novartis collaborate to develop novel treatments for hearing loss and balance disorders

PCI Biotech AS completes second dose group in phase I/II study of Amphinex

CEL-SCI completes validation of its GMP manufacturing facility

BioVex's Phase 3 melanoma study amended to include first line patients

FDA approves minimally invasive procedure for treating benign and malignant tumors

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News